
Opinion|Videos|August 9, 2024
Future Predictions for Intravenous and Subcutaneous Biologics
An expert in the field of rheumatology predicts how the treatment landscape will evolve for intravenous and subcutaneous therapies.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- How has the introduction of IV biosimilars impacted your treatment decisions? Do you see a role for subcutaneous biosimilars in the future?
- Do you foresee IV and subcutaneous route of administration always having a role moving forward? How do you see the treatment landscape changing?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first treatment for chronic hepatitis D virus
2
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
3
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
4
Recent COVID vaccination cuts household transmission by half
5

























